SCHEMBL9909312

SCHEMBL9909312

COC(=O)c1ccc2c(Cl)cnc(-c3c(OC)ccc(F)c3F)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 5/20 0.47
CTSA P10619 1/20 0.42
KCNQ3 O43525 1/20 0.42
KCNQ2 O43526 1/20 0.42
SCN9A Q15858 1/20 0.42
KMT2A Q03164 3/20 0.40
GLA P06280 1/20 0.40
CSNK2A1 P68400 1/20 0.39
TTR P02766 1/20 0.39
PLG P00747 1/20 0.39
PLAU P00749 1/20 0.39
MAPT P10636 3/20 0.39
MEN1 O00255 2/20 0.39
CASP3 P42574 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15500531 0.91 HTR5A (0.44) HTR5AKCNQ3KCNQ2SCN9AKMT2A
SCHEMBL9909316 0.90 PLG (0.48) HTR5ACTSAKCNQ3KCNQ2TTR
SCHEMBL9908008 0.89 HTR5A (0.51) HTR5AKMT2ACSNK2A1TTRMAPT
SCHEMBL9909263 0.87 HTR5A (0.60) HTR5ACTSAKCNQ3KCNQ2SCN9A
SCHEMBL9909298 0.85 HTR5A (0.49) HTR5AKCNQ3KCNQ2KMT2AGLA
SCHEMBL9909318 0.85 HTR5A (0.68) HTR5ACTSAPLGPLAU
SCHEMBL9907998 0.84 HTR5A (0.52) HTR5ACTSAKCNQ3KCNQ2KMT2A
SCHEMBL9105219 0.83 HTR5A (0.54) HTR5AKMT2ACSNK2A1TTRMAPT
SCHEMBL9907437 0.83 HTR5A (0.54) HTR5AKMT2ACSNK2A1MAPTMEN1
SCHEMBL9907999 0.82 HTR5A (0.48) HTR5ACTSAKMT2AGLACSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
WO-2011016504-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E HTR5A 1/4885CTSA 1917/4885KCNQ3 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.